Use of cladribine for treating neuromyelitis optica

• 收藏
• 分享

专利权人:

Chord Therapeutics S.a.r.l.

发明人:

Roach, Arthur Henry,Rejdak, Konrad

申请号：

AU2015212613

公开号：

AU2015212613A1

申请日:

2015.01.27

申请国别(地区):

AU

年份:

2016

代理人:

摘要：

2-Chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO - IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO - IgG seropositivity.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/